Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17360
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBoulos, Daniel-
dc.contributor.authorNgian, Gene-Siew-
dc.contributor.authorRajadurai, Anton-
dc.contributor.authorElford, Kathleen-
dc.contributor.authorStevens, Wendy-
dc.contributor.authorProudman, Susanna-
dc.contributor.authorOwen, Claire-
dc.contributor.authorRoddy, Janet-
dc.contributor.authorNikpour, Mandana-
dc.contributor.authorYoussef, Peter-
dc.contributor.authorHill, Catherine-
dc.contributor.authorSahhar, Joanne-
dc.date2017-
dc.date.accessioned2018-04-04T04:29:49Z-
dc.date.available2018-04-04T04:29:49Z-
dc.date.issued2017-04-
dc.identifier.citationInternational journal of rheumatic diseases 2017; 20(4): 481-488-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17360-
dc.description.abstractTo assess the long-term efficacy and tolerability of mycophenolate mofetil (MMF) in patients with diffuse cutaneous systemic sclerosis (dcSSc). Patients enrolled in the Australian Scleroderma Cohort study with dcSSc and baseline modified Rodnan skin score (mRSS) ≥ 12 who were treated for a minimum of 12 months with MMF for the primary indication of skin disease were included and their prospectively collected data retrieved. Change in mRSS, the proportion with a clinically significant improvement (reduction in mRSS ≥ 5 from baseline) and adverse effects due to therapy were determined. Seventy-four participants treated with MMF were identified and of these, 42 met inclusion criteria. The mean age was 53 ± 12 years, with mean disease duration at MMF commencement of 4.8 ± 4.3 years. Twenty-one participants (50%) commenced MMF within 2 years of disease onset and the mean duration of therapy was 2.7 ± 1.7 years. The mean mRSS at baseline was 25.9 ± 9.2 with a reduction of 3.7 ± 7.1 (P = 0.07) after 1 year of therapy, 7.6 ± 8.3 after 2 years (P = 0.01) and 10.5 ± 10.3 after 5 years (P < 0.01). Response to treatment was not affected by disease duration at MMF commencement or baseline skin score. Eighteen participants (43%) demonstrated clinically significant improvement after 1 year, increasing to 92% after 4 years. Two participants (5%) ceased MMF due to adverse effects. MMF was associated with a modest improvement in mRSS and was well tolerated in the treatment of dcSSc. Given the natural history of dcSSc where skin involvement can spontaneously improve, randomized, placebo-controlled studies are required to confirm whether improvement can be attributed to MMF therapy.-
dc.language.isoeng-
dc.subjectdiffuse-
dc.subjectmycophenolate mofetil-
dc.subjectscleroderma-
dc.subjectsystemic sclerosis-
dc.titleLong-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.-
dc.typeJournal Articleen
dc.identifier.journaltitleInternational journal of rheumatic diseases-
dc.identifier.affiliationDepartment of Rheumatology, Monash Health, Melbourne, Victoria, Australia-
dc.identifier.affiliationDepartment of Rheumatology, Royal Adelaide Hospital, Adelaide, South Australia, Australia-
dc.identifier.affiliationDiscipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia-
dc.identifier.affiliationDepartment of Rheumatology, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Melbourne, Victoria, Australia-
dc.identifier.affiliationDepartment of Rheumatology, Royal Perth Hospital, Perth, Western Australia, Australia-
dc.identifier.affiliationDepartment of Rheumatology, St Vincent's Health, Melbourne, Victoria, Australia-
dc.identifier.affiliationDepartment of Rheumatology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia-
dc.identifier.affiliationDepartment of Rheumatology, Queen Elizabeth Hospital, Adelaide, South Australia, Australia-
dc.identifier.affiliationDepartment of Medicine, Monash University, Melbourne, Victoria, Australia-
dc.identifier.doi10.1111/1756-185X.13035-
dc.type.contentTexten
dc.identifier.pubmedid28337853-
dc.type.austinJournal Article-
dc.type.austinMulticenter Study-
dc.type.austinObservational Study-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.